According to NICE guidelines, laparoscopy is the most reliable method of diagnosing endometriosis in patients who are suspected to have the condition. Even if a transvaginal or transabdominal ultrasound appears normal, laparoscopy should still be considered. If a thorough laparoscopy is conducted and no signs of endometriosis are found, the patient should be informed that they do not have the condition and offered alternative treatment options.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

The appropriate option for emergency contraception in this case is ulipristal, which can be prescribed up to 120 hours after unprotected sexual intercourse. Levonorgestrel, which must be taken within 72 hours, is not a suitable option. Insertion of an intrauterine device or system is also inappropriate as the patient declined invasive contraception. Mifepristone is not licensed for emergency contraception.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

The UK Government implemented legal modifications in October 2015 regarding the response of doctors in England and Wales to instances of female genital mutilation (FGM). As per the guidelines of the General Medical Council (GMC), doctors are required to report all cases of FGM in individuals under the age of 18 to the police. This can be done by contacting 101 or using the established local channels. Reporting is compulsory to align with our responsibilities towards child protection and safeguarding.

Understanding Female Genital Mutilation

Female genital mutilation (FGM) is a term used to describe any procedure that involves the partial or complete removal of the external female genitalia or any other injury to the female genital organs for non-medical reasons. The World Health Organization (WHO) has classified FGM into four types. Type 1 involves the partial or total removal of the clitoris and/or the prepuce, while type 2 involves the partial or total removal of the clitoris and the labia minora, with or without excision of the labia majora. Type 3 involves the narrowing of the vaginal orifice with the creation of a covering seal by cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris. Finally, type 4 includes all other harmful procedures to the female genitalia for non-medical purposes, such as pricking, piercing, incising, scraping, and cauterization. It is important to understand the different types of FGM to raise awareness and prevent this harmful practice.

If two consecutive samples are deemed inadequate during cervical cancer screening, the correct course of action is to refer the patient for colposcopy. Repeating the smear in 1 or 3 months is not appropriate as two inadequate samples have already been taken. Requesting hrHPV testing from the laboratory is also not useful if the sample is inadequate. Referring the patient to gynaecology is not necessary, and instead, a referral for colposcopy should be made.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

To address the patient’s condition, it is recommended to refer her to the postmenopausal bleeding clinic for an endometrial biopsy. According to the Faculty of Sexual and Reproductive Health, women aged 45 years who use hormonal contraception and experience persistent problematic bleeding or a change in bleeding pattern should undergo endometrial biopsy. Given that the patient is obese and has type two diabetes, both of which are risk factors for endometrial malignancy, watchful waiting and reassurance are not appropriate responses. While the Mirena may be nearing the end of its lifespan after 4 years of insertion, bleeding cannot be attributed to this without ruling out underlying pathology. Hormone replacement therapy is not recommended for this patient at this time.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

If there is suspicion of ovarian cancer and an abdominal or pelvic mass is present, it is not necessary to perform a CA125 and US test. Instead, the patient should be immediately referred to gynaecology. Prescribing loperamide and buscopan for symptoms of irritable bowel syndrome in women over 50 years old is not appropriate as these symptoms could indicate ovarian cancer and require investigation. While waiting for the results of CA125 and ultrasound tests is usually recommended for suspected ovarian cancer patients, urgent referral to gynaecology is necessary in this case due to the presence of an abdominal mass. Although CA125 measurement should still be performed, waiting for test results to determine the need for urgent referral is not appropriate as guidelines already recommend it.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

Trichomonas vaginalis is a protozoan that causes trichomoniasis, characterized by a green-yellow discharge with a foul odor. Men usually do not show symptoms, while women may experience dysuria, frequent urination, and itching. Treatment involves taking oral metronidazole for seven days. Although complications are rare, pregnant women with trichomoniasis may experience premature labor. The disease is sexually transmitted, so a thorough sexual history should be taken.

Neisseria gonorrhoeae is a diplococcus that causes gonorrhea, which may be asymptomatic in women but can cause vaginal discharge and painful urination. Treatment involves a single intramuscular injection of ceftriaxone 500 mg.

Chlamydia trachomatis is an intracellular organism that causes chlamydia, which is often asymptomatic in women but may cause cervicitis, urethritis, or salpingitis. Treatment involves a single oral dose of azithromycin 1 g.

Candida albicans causes thrush, which is characterized by white curd-like discharge, red and sore vulva, and hyphae visible on microscopy. Treatment involves using clotrimazole in pessary or topical form, with fluconazole used for resistant cases.

Treponema pallidum causes syphilis, which may present as a painless ulcer in the genital area called a chancre. Treatment involves using benzathine penicillin. While secondary and further stages of syphilis are becoming rare, it is important to seek treatment promptly.

The most probable diagnosis for this patient is ovarian torsion, which is common in women of reproductive age. Symptoms include pain in the iliac fossa that can spread to the loin, groin, or back, as well as nausea and vomiting. An adnexal mass may be present on examination, which is often caused by an ovarian cyst or neoplasm that has disrupted the ovary’s normal position and caused torsion. In some cases, a low-grade fever may also be present if ovarian necrosis has occurred.

It is important to rule out ectopic pregnancy as a differential diagnosis, which can be done with a pregnancy test regardless of reported contraception. Vaginal bleeding may help differentiate between the two conditions. However, since the patient’s menstrual period started 7 days ago and she uses condoms for contraception, ectopic pregnancy is less likely than ovarian torsion.

Appendicitis is also a possible cause of this presentation, but it typically presents with diffuse abdominal pain that later localizes to the right iliac fossa. In appendicitis, pain can be reproduced in the right iliac fossa by palpating the left iliac fossa (Rovsing’s sign), but left iliac fossa pain would not be the presenting symptom.

Mittelschmerz, which is mild pain in the right iliac fossa, could also be a possible cause, but it would not be associated with nausea and vomiting.

Causes of Pelvic Pain in Women

Pelvic pain is a common complaint among women, with primary dysmenorrhoea being the most frequent cause. Mittelschmerz, or pain during ovulation, may also occur. However, there are other conditions that can cause pelvic pain, which can be acute or chronic in nature.

Acute pelvic pain can be caused by conditions such as ectopic pregnancy, urinary tract infection, appendicitis, pelvic inflammatory disease, and ovarian torsion. Ectopic pregnancy is characterized by lower abdominal pain and vaginal bleeding in women with a history of 6-8 weeks of amenorrhoea. Urinary tract infection may cause dysuria and frequency, while appendicitis may present with pain in the central abdomen before localizing to the right iliac fossa. Pelvic inflammatory disease may cause pelvic pain, fever, deep dyspareunia, vaginal discharge, dysuria, and menstrual irregularities. Ovarian torsion, on the other hand, may cause sudden onset unilateral lower abdominal pain, nausea, vomiting, and a tender adnexal mass on examination.

Chronic pelvic pain, on the other hand, may be caused by conditions such as endometriosis, irritable bowel syndrome, ovarian cysts, and urogenital prolapse. Endometriosis is characterized by chronic pelvic pain, dysmenorrhoea, deep dyspareunia, and subfertility. Irritable bowel syndrome is a common condition that presents with abdominal pain, bloating, and change in bowel habit. Ovarian cysts may cause a dull ache that is intermittent or only occurs during intercourse, while urogenital prolapse may cause a sensation of pressure, heaviness, and urinary symptoms such as incontinence, frequency, and urgency.

In summary, pelvic pain in women can be caused by various conditions, both acute and chronic. It is important to seek medical attention if the pain is severe or persistent, or if there are other concerning symptoms present.

Management of Ectopic Pregnancy: Laparoscopic Salpingostomy

Ectopic pregnancy, defined as pregnancy occurring outside the uterine cavity, is a serious condition that requires prompt diagnosis and management. Laparoscopic salpingostomy is a preferred method of treatment for ectopic pregnancies, but it may not be suitable for all cases.

Diagnosis of ectopic pregnancy can be challenging as it presents with non-specific symptoms such as lower abdominal/pelvic pain, vaginal discharge, and urinary symptoms. A urinary pregnancy test and an ultrasound scan are necessary to confirm the diagnosis. In emergency cases where the patient is haemodynamically unstable, laparotomy may be necessary.

Laparoscopic salpingectomy, the removal of the tube containing the ectopic pregnancy, is the gold standard for treating ectopic pregnancies. However, if the patient has only one Fallopian tube, laparoscopic salpingostomy, where the tube is incised, the ectopic removed, and the tube repaired, is preferred to preserve the patient’s chances of conceiving naturally in the future.

A single intramuscular dose of methotrexate may be used as medical management of an ectopic pregnancy, but only if certain conditions are met. These include the absence of significant pain, an unruptured ectopic pregnancy, and a serum βhCG level of <1500 iu/l. In cases where right iliac fossa pain is present in a woman of reproductive age, associated with vaginal discharge, cervical excitation, and the last menstrual period of >4 weeks before, ectopic pregnancy should be treated as the primary diagnosis until proven otherwise. Referral to the surgical team may be necessary to rule out appendicitis.

In conclusion, laparoscopic salpingostomy is a suitable method of treatment for ectopic pregnancies in patients with only one Fallopian tube. Early diagnosis and prompt management are crucial in ensuring the best possible outcome for the patient.

Urodynamic studies are necessary when there is a lack of clarity in diagnosis or when surgery is being considered.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

If a patient presents with primary amenorrhoea and raised FSH/LH levels, it is important to consider the possibility of gonadal dysgenesis, such as Turner’s syndrome. This condition is characterized by the presence of only one X chromosome or a deletion of the short arm of one X chromosome, which can result in widely spaced nipples and other physical characteristics. In Turner’s syndrome, the lack of estrogen and progesterone production by the ovaries leads to an increase in FSH/LH levels as a compensatory mechanism. Therefore, an increase in FSH/LH levels is consistent with this diagnosis. Cyclical pain due to an imperforate hymen typically presents with secondary sexual characteristics, while increased prolactin levels are associated with galactosemia, and increased androgen levels are associated with polycystic ovarian syndrome. In the case described, a diagnosis of Turner’s syndrome is likely, and serum estrogen levels would not be expected to be elevated due to gonadal dysgenesis.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

This individual has reached the postmenopausal stage, indicated by the absence of menstruation for 12 consecutive months. However, despite being postmenopausal, she still requires contraception as she is below the age of 50. According to guidelines, women who use non-hormonal contraception can discontinue after one year of amenorrhea if they are over 50 years old, and after two years if they are under 50 years old. Given her history of breast cancer, a copper coil is the most suitable option as all other hormonal methods are classified as UKMEC Category 3, which may pose an unacceptable risk.

Women over 40 years old still need effective contraception until menopause. All methods of contraception are generally safe for this age group, except for the COCP and Depo-Provera which have some limitations. COCP use may help maintain bone mineral density and reduce menopausal symptoms, but a pill with less than 30 µg ethinylestradiol may be more suitable for women over 40. Depo-Provera use is associated with a small loss in bone mineral density and may cause a delay in the return of fertility for up to 1 year for women over 40. The FSRH provides guidance on how to stop different methods of contraception based on age and amenorrhea status. HRT cannot be relied upon for contraception, and a separate method is needed. The POP may be used with HRT as long as the HRT has a progesterone component, while the IUS is licensed to provide the progesterone component of HRT.

If analgesia is ineffective in treating endometriosis, the first-line option to try is the combined oral contraceptive pill or a progesterone.

The patient’s chronic cyclical pelvic pain, dyspareunia, secondary dysmenorrhoea, and pain with bowel movements are consistent with endometriosis. The examination findings also support this diagnosis. Paracetamol with or without an NSAID (such as mefenamic acid or ibuprofen) is the initial treatment for endometriosis. If these medications do not work, hormonal therapy (such as the combined oral contraceptive pill or medroxyprogesterone acetate) is the second-line option.

Since the patient plans to start a family within the next year, the combined oral contraceptive pill is the more appropriate choice as it does not delay fertility. Medroxyprogesterone acetate, also known as Depo Provera, provides contraception for up to 12 weeks but can delay fertility for up to 12 months and is irreversible once given. Additionally, the patient’s BMI of 34 kg/m² is a known risk factor for weight gain, which is a potential side effect of the injectable contraceptive.

Offering mefenamic acid is not recommended as analgesia has already been tried without success. If analgesia is ineffective in treating endometriosis, the combined oral contraceptive pill or a progesterone should be considered.

Referring the patient for consideration of GnRH analogue is not appropriate at this stage. This option is only considered if hormonal therapy is ineffective. It is important to trial the combined oral contraceptive pill before considering a referral.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

According to NICE guidelines for cervical screening, if the smear test is inadequate or the high-risk human papillomavirus (hrHPV) test result is unavailable, the sample should be repeated within 3 months. Therefore, repeating the sample in 3 months is the correct course of action. Repeating HPV testing in 1 week would not change the management plan as Sarah has already tested positive for hrHPV and requires an adequate cervical cytology result. Colposcopy is only necessary if there are two consecutive inadequate results. Waiting 12 months to repeat the sample would be inappropriate as it would be too long between tests. Similarly, returning Sarah to routine recall is not appropriate as she requires an adequate cytology result.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

This condition is rare, but it is more common in pregnancies that have exceeded 20 weeks of gestation.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Pelvic floor muscle training is the most effective and cost-efficient treatment for stress urinary incontinence in women. Ring pessaries can also be used as a non-surgical option for pelvic organ prolapse. Oxybutynin is typically used for urge incontinence, but in this scenario, the woman only experiences stress incontinence. While a referral to urogynaecology may be considered for further investigation or surgery, it is not necessary to do so urgently. Pelvic floor exercises should be attempted for at least 3 months under the guidance of a continence adviser, specialist nurse, or women’s health physiotherapist. As the woman’s symptoms persist despite 6 months of trying this approach, it would be inappropriate to suggest continuing with the same strategy.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

The patient’s symptoms of dysmenorrhoea, dyspareunia, and subfertility are classic signs of endometriosis, a common condition where endometrial tissue grows outside of the uterus. The presence of uterosacral nodularity and tenderness further supports this diagnosis. Some patients with endometriosis may also experience urinary symptoms due to bladder involvement or adhesions. Uterine leiomyoma, or fibroid, is a common pelvic tumor that causes abnormal uterine bleeding, pelvic pressure and pain, and reproductive dysfunction. However, it does not typically present with uterosacral nodularity and tenderness on rectal examination. Interstitial cystitis causes urinary frequency and urgency, with pain relieved upon voiding. Pelvic inflammatory disease presents with fever, nausea, acute pain, malodorous vaginal discharge, and cervical motion tenderness/adnexal tenderness.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Hysterectomy is the most effective treatment for menorrhagia caused by large fibroids, which are benign tumors of smooth muscle that can grow in response to hormones. Risk factors for fibroids include obesity, early menarche, African-American origin, and a family history of fibroids. Symptoms of fibroids include heavy periods, anemia, abdominal discomfort, and pressure symptoms. Diagnosis is made through pelvic ultrasound. Medical management with NSAIDs or tranexamic acid can be tried first, but if it fails, surgical management is necessary. Uterine-sparing surgeries like myomectomy or uterine artery embolization can be considered for women who want to preserve their fertility, but hysterectomy is the definitive method of treatment for women who have completed their family or have severe symptoms. The levonorgestrel intrauterine system is not recommended for women with large fibroids causing uterine distortion. Mefenamic acid is less effective than tranexamic acid for fibroid-related menorrhagia. Myomectomy is not a definitive method of management as fibroids can recur. Uterine artery embolization is an option for women who want to preserve their uterus but not their fertility, but its effect on fertility and pregnancy is not well established.

If a cervical smear test is hrHPV positive but cytologically normal, the recommended course of action is to repeat the test in 12 months. This is in contrast to negative hrHPV results, which are returned to normal recall. Abnormal cytology results require colposcopy, but normal cytology results do not. It is important to note that returning to normal recall is not appropriate in this case, as the patient’s higher risk status warrants a repeat test sooner than the standard 3-year interval. Repeating the test within 3 or 6 months is also not recommended.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Understanding Puerperal Pyrexia

Puerperal pyrexia is a condition that occurs when a woman experiences a fever of more than 38ºC within the first 14 days after giving birth. The most common cause of this condition is endometritis, which is an infection of the lining of the uterus. Other causes include urinary tract infections, wound infections, mastitis, and venous thromboembolism.

If a woman is suspected of having endometritis, it is important to seek medical attention immediately. Treatment typically involves intravenous antibiotics such as clindamycin and gentamicin until the patient is afebrile for more than 24 hours. It is important to note that puerperal pyrexia can be a serious condition and should not be ignored. By understanding the causes and seeking prompt medical attention, women can receive the necessary treatment to recover from this condition.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

Common Causes of Vaginal Discharge: Symptoms and Treatment

Bacterial vaginosis, Trichomonas vaginalis, Candidiasis, gonorrhoeae, and Pelvic inflammatory disease are some of the most common causes of vaginal discharge in women.

Bacterial vaginosis is caused by an overgrowth of anaerobic bacteria and loss of lactobacilli in the vagina. It presents with a grey-white, thin discharge with a fishy odour and an increased vaginal pH. Metronidazole is the treatment of choice.

Trichomonas vaginalis is a sexually transmitted infection that presents with a yellow-green discharge and an erythematosus cervix with a punctate exudate.

Candidiasis is a fungal infection associated with pruritus, burning, erythema, and oedema of the vestibule. The vaginal discharge is thick, curd-like, and white.

gonorrhoeae can be asymptomatic or present with abdominal pain, mucopurulent discharge, cervicitis, dyspareunia, or abnormal bleeding.

Pelvic inflammatory disease is the result of an ascending infection and presents with dyspareunia, lower abdominal pain, menstrual irregularities, irregular bleeding, and a blood stained, purulent vaginal discharge. Cervicitis and cervical excitation are also present.

Proper diagnosis and treatment are essential to prevent complications and improve the quality of life of affected women.

MRI is the most effective imaging technique for diagnosing adenomyosis, which is the presence of endometrial tissue in the myometrium. While ultrasound can also aid in diagnosis, it is not as reliable as MRI. Laparoscopy is used to diagnose endometriosis, but it cannot detect adenomyosis as it occurs within the uterine wall. CT is not a suitable imaging technique for adenomyosis as it cannot differentiate between different types of tissue. Hysterosalpingography is used for imaging the uterine lining and fallopian tubes, typically during fertility treatment, but it cannot provide an image of the myometrium.

Understanding Adenomyosis

Adenomyosis is a medical condition that occurs when endometrial tissue grows within the muscular walls of the uterus. This condition is more common in women who have had multiple pregnancies and are nearing the end of their reproductive years. Symptoms of adenomyosis include painful menstrual cramps, heavy menstrual bleeding, and an enlarged and tender uterus.

To diagnose adenomyosis, doctors typically use magnetic resonance imaging (MRI) as it is the most effective method. Treatment options for adenomyosis include managing symptoms with pain relief medication, using tranexamic acid to control heavy bleeding, and administering gonadotropin-releasing hormone (GnRH) agonists to reduce estrogen levels. In severe cases, uterine artery embolization or hysterectomy may be necessary. Hysterectomy is considered the definitive treatment for adenomyosis.

In summary, adenomyosis is a condition that affects the uterus and can cause painful menstrual cramps, heavy bleeding, and an enlarged uterus. It is more common in women who have had multiple pregnancies and are nearing the end of their reproductive years. Diagnosis is typically done through MRI, and treatment options include managing symptoms, medication, and surgery.

Secondary amenorrhoea is a common issue in highly athletic women, often caused by hypothalamic hypogonadism. This is the case for a young woman who is training for a marathon and has experienced oligomenorrhoea in the past. When a woman’s body has low levels of fat, the hypothalamus releases less gonadotrophin-releasing hormone, leading to hypogonadism. This is believed to occur because very low-fat levels are not conducive to successful pregnancy in females.

While an ultrasound may reveal many cysts on the ovaries, this woman does not meet the Rotterdam criteria for a diagnosis of polycystic ovary syndrome (PCOS). Although she experiences oligomenorrhoea, she does not exhibit signs of hyperandrogenism and has a lower-normal weight. It is also possible that she is pregnant, and a urine or serum pregnancy test should be conducted to rule out this possibility, even if she claims not to be sexually active.

While primary ovarian failure is a potential cause, it is not the most likely explanation in this case. However, it should still be investigated with gonadotrophins. If ovarian failure is present, gonadotrophin levels will be elevated, indicating that the hypothalamus and pituitary gland are not providing negative feedback on hormone release.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

Common Causes of Abnormal Uterine Bleeding in Women

Abnormal uterine bleeding is a common gynecological problem that can have various underlying causes. Here are some of the most common causes of abnormal uterine bleeding in women:

Endometriosis: This condition occurs when the endometrial tissue grows outside the uterus, usually in the ovaries or pelvic cavity. Symptoms include painful periods, painful intercourse, painful bowel movements, and adnexal tenderness. Endometriosis can also lead to infertility.

Ovulatory dysfunctional uterine bleeding: This condition is caused by excessive production of vasoconstrictive prostaglandins in the endometrium during a menstrual period. Symptoms include heavy and painful periods. Non-steroidal anti-inflammatory drugs are the treatment of choice.

Cervical cancer: This type of cancer is associated with human papillomavirus infection, smoking, early intercourse, multiple sexual partners, use of oral contraceptives, and immunosuppression. Symptoms include vaginal spotting, post-coital bleeding, dyspareunia, and vaginal discharge. Cervical cancer is rare before the age of 25 and is unlikely to cause dysmenorrhea, dyspareunia, dyschezia, or adnexal tenderness.

Submucosal leiomyoma: This is a benign neoplastic mass of myometrial origin that protrudes into the intrauterine cavity. Symptoms include heavy and painful periods, but acute pain is rare.

Endometrial polyps: These are masses of endometrial tissue attached to the inner surface of the uterus. They are more common around menopausal age and can cause heavy or irregular bleeding. They are usually not associated with pain or menstrual cramps and are not pre-malignant.

Understanding the Common Causes of Abnormal Uterine Bleeding in Women

During the initial 6 months after the intrauterine system is inserted, experiencing irregular bleeding is a typical adverse effect. However, over time, the majority of women who use the IUS will experience reduced or absent menstrual periods, which is advantageous for those who experience heavy menstrual bleeding or prefer not to have periods.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucous. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

Diagnosis of Hydatidiform Mole in Early Pregnancy: Clinical Features and Treatment Options

Hydatidiform mole is a type of gestational trophoblastic disease that occurs due to abnormal fertilization of an ovum, resulting in a non-viable pregnancy. The condition presents with clinical features such as vaginal bleeding, excessive vomiting, a large-for-dates uterus, and a very high hCG level. Pelvic ultrasound may reveal a ‘snowstorm’ appearance from the intrauterine mass and cystic components.

The diagnosis of hydatidiform mole is crucial as it determines the treatment options. If the patient wishes to retain her fertility, dilation and evacuation are offered. However, if fertility is not desired, a hysterectomy is recommended. The former has fewer post-operative complications but carries a higher risk of post-operative gestational trophoblastic neoplasia. Antiemetics are prescribed to manage nausea and vomiting.

Twin pregnancy and complete miscarriage are differential diagnoses, but the absence of fetal parts and the grossly elevated hCG level point towards hydatidiform mole. Pre-eclampsia cannot be diagnosed before the second trimester, and endometrial carcinoma is unlikely to cause a uterine mass or elevated hCG levels.

In conclusion, early diagnosis of hydatidiform mole is crucial for appropriate management and prevention of complications.

Endometriosis is characterized by pelvic pain, dysmenorrhoea, dyspareunia, and subfertility. The symptoms experienced by the patient in this case suggest the presence of intra-pelvic pathology, including a retroverted uterus and age-related factors. Chlamydia infection is often asymptomatic and does not typically cause dysmenorrhoea, although dyspareunia may occur. Lower abdominal pain may be caused by ovarian cysts, while ectopic pregnancy is associated with amenorrhoea and lower abdominal pain.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

If pelvic floor muscle exercises are ineffective and surgical intervention is not desired, duloxetine may be used to manage stress incontinence, as per NICE guidance from 2019. It should be noted that bladder retraining is not recommended for this type of incontinence, and oxybutynin is only indicated for urge incontinence if bladder retraining has failed. Referral for urodynamics testing is also not recommended, with urogynaecology being the preferred option for secondary care. Additionally, NICE does not recommend continuing pelvic floor exercises for an additional 3 months.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

The method of contraception that is commonly linked to weight gain is injectable contraception, which includes Depo-Provera. The combined oral contraceptive pill has been associated with an increased risk of venous thromboembolic disease, breast cancer, and cervical cancer, but there is no evidence to suggest that it causes weight gain. Implantable contraceptives like Implanon are typically associated with irregular or heavy bleeding, but not weight gain. Intrauterine devices, such as the copper coil, are known to cause heavier and more painful periods, but they are not associated with weight gain.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.